Hookipa Pharma (NASDAQ:HOOK) Trading 4% Higher

Shares of Hookipa Pharma Inc (NASDAQ:HOOK) traded up 4% on Friday . The stock traded as high as $0.69 and last traded at $0.68. 279,959 shares were traded during trading, a decline of 61% from the average session volume of 718,850 shares. The stock had previously closed at $0.66.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. HC Wainwright dropped their target price on Hookipa Pharma from $8.00 to $6.50 and set a “buy” rating for the company in a report on Friday, August 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $7.00 price objective on shares of Hookipa Pharma in a report on Friday, June 30th.

Hookipa Pharma Trading Up 4.0 %

The company has a market cap of $57.17 million, a PE ratio of -0.75 and a beta of 0.69. The stock has a 50 day moving average price of $0.78 and a 200 day moving average price of $0.94.

Hookipa Pharma (NASDAQ:HOOK) last released its earnings results on Thursday, August 10th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.01). The firm had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $3.54 million. Hookipa Pharma had a negative net margin of 429.13% and a negative return on equity of 66.35%. Equities analysts expect that Hookipa Pharma Inc will post -1.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Hookipa Pharma by 22.6% during the 1st quarter. Vanguard Group Inc. now owns 1,118,871 shares of the company’s stock valued at $2,551,000 after buying an additional 206,309 shares in the last quarter. State Street Corp increased its holdings in shares of Hookipa Pharma by 29.3% in the 1st quarter. State Street Corp now owns 428,534 shares of the company’s stock worth $977,000 after purchasing an additional 97,057 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Hookipa Pharma by 117.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 87,217 shares of the company’s stock worth $199,000 after purchasing an additional 47,168 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Hookipa Pharma by 54.5% in the 1st quarter. Royal Bank of Canada now owns 255,883 shares of the company’s stock worth $584,000 after purchasing an additional 90,232 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Hookipa Pharma in the 1st quarter worth $1,434,000. Hedge funds and other institutional investors own 83.02% of the company’s stock.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.